ProQR Therapeutics (PRQR) Shares Soar 17.59% on Clinical Trial Submission

ProQR Therapeutics (PRQR) shares surged to their highest level since February 2025 today, with an intraday gain of 17.59%.

The strategy of buying PRQR shares after they reached a recent high and holding for 1 week showed poor performance. The annualized return was -23.4%, significantly underperforming the market. This indicates that relying on recent highs as a buying trigger and holding for a short duration is not a profitable strategy for PRQR.

ProQR Therapeutics has made significant strides in advancing its RNA editing therapy. On June 26, 2025, the company announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency for a Phase 1 clinical trial of their RNA editing therapy, AX-0810. This marks the first clinical application of ProQR’s Axiomer RNA editing platform, a pivotal development in the company's efforts to address cholestatic liver diseases. The successful submission of the CTA is a testament to ProQR's innovative approach and its potential to revolutionize the treatment landscape for these conditions.

Analysts have also weighed in on ProQR Therapeutics' recent developments. On June 27, 2025, Cantor Fitzgerald analyst Timur Ivannikov reiterated an "Overweight" rating for the company. Additionally, JMP Securities maintained a Market Outperform rating with an $8.00 price target, while Oppenheimer lowered their target price from $15.00 to $9.00 but kept an "outperform" rating. The average target price offered by analysts is approximately $9.17, reflecting a generally positive outlook on the company's prospects.